Table 1.
Demographics of Participants in Current Analysisa
| Characteristic | Group A (n = 22) | Group B (n = 15) | Group C (n = 21) |
|---|---|---|---|
| Age, median (range), y | 63 (24–88) | 65 (19–90) | 58 (26–88) |
| Female sex, no. (%) | 13 (59) | 12 (73) | 14 (64) |
| White race, no. (%) | 22 (100) | 15 (93) | 22 (100) |
| Antibiotic used at screening, no. (%) | |||
| Vancomycin | 20 (91) | 13 (87) | 19 (90) |
| Fidaxomicin | 1 (4.5) | 1 (6) | 1 (5) |
| Metronidazole | 1 (4.5) | 0 (0) | 0 (0) |
| Vancomycin + other | 0 (0) | 1 (7) | 1 (5) |
| No. of CDI episodes, median (range) | 3 (3–7) | 3 (2–5) | 4 (3–10) |
| Duration of CDI episodes, median (range), d | 13 (2–64) | 17 (3–47) | 14 (2–51) |
Abbreviation: CDI, Clostridioides difficile infection.
aGroup A received 2 doses of RBX2660; group B, 2 doses of placebo; and group C, 1 dose of RBX2660 followed by 1 dose of placebo. There was no evidence of significant differences among treatment groups with respect to age, sex, prior episodes, duration of enrolling episode, or antibiotic administered for the enrolling episode (Kruskal-Wallis test).